Our new therapeutic could revolutionalise the treatment of these indications alone or in combination with other existing treatments. At AVIPERO, we aim to take the development of the treatment to early clinical trials in humans focusing initially on Parkinson’s disease with the view to progressing with development in emphysema and arthritis under strategic alliances with suitable pharmaceutical companies.

Cell death is hallmark of many chronic diseases such as dementias in the brain, heart attacks, asthma, cancer and skin wound healing amongst many. The future applicability of AVIPERO’s treatment could extend beyond the tested indications.